Chardan Capital Reaffirms Buy Rating for Seres Therapeutics (NASDAQ:MCRB)

Seres Therapeutics (NASDAQ:MCRB)‘s stock had its “buy” rating reissued by equities researchers at Chardan Capital in a report released on Wednesday,Benzinga reports. They presently have a $1.25 price objective on the biotechnology company’s stock. Chardan Capital’s target price suggests a potential upside of 111.11% from the stock’s previous close.

MCRB has been the subject of a number of other reports. Canaccord Genuity Group reaffirmed a “buy” rating and set a $10.00 price target on shares of Seres Therapeutics in a research note on Friday, September 13th. StockNews.com lowered Seres Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, August 13th. Finally, JPMorgan Chase & Co. downgraded Seres Therapeutics from a “neutral” rating to an “underweight” rating in a research report on Thursday, October 24th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $5.08.

Seres Therapeutics Stock Performance

Shares of NASDAQ:MCRB opened at $0.59 on Wednesday. The company has a market capitalization of $100.78 million, a PE ratio of -0.50 and a beta of 2.06. The stock has a fifty day moving average of $0.86 and a 200-day moving average of $0.92. Seres Therapeutics has a one year low of $0.54 and a one year high of $2.05.

Seres Therapeutics (NASDAQ:MCRB) last released its quarterly earnings results on Tuesday, August 13th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.08. During the same quarter last year, the business posted $0.36 EPS. As a group, research analysts forecast that Seres Therapeutics will post -0.92 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. bought a new position in Seres Therapeutics in the first quarter valued at approximately $39,000. Vanguard Group Inc. increased its holdings in Seres Therapeutics by 12.1% during the 1st quarter. Vanguard Group Inc. now owns 6,734,821 shares of the biotechnology company’s stock worth $5,213,000 after purchasing an additional 729,514 shares in the last quarter. Virtu Financial LLC acquired a new stake in shares of Seres Therapeutics in the 1st quarter valued at about $73,000. Providence Wealth Advisors LLC raised its stake in shares of Seres Therapeutics by 49.5% in the 2nd quarter. Providence Wealth Advisors LLC now owns 76,250 shares of the biotechnology company’s stock valued at $58,000 after purchasing an additional 25,250 shares during the period. Finally, Point72 DIFC Ltd bought a new stake in shares of Seres Therapeutics in the second quarter valued at about $64,000. 59.34% of the stock is owned by institutional investors and hedge funds.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.